Telomerase Activator and Retinal Amyloid
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02530255|
Recruitment Status : Completed
First Posted : August 21, 2015
Last Update Posted : July 5, 2019
A method of detecting amyloid in the retina has been developed. A specially designed retinal camera will directly visualze and record retinal amyloid and via image processing will generate a number: the retinal amyloid index (RAI). The amount of retinal amyloid correlates with cerebral amyloid and has a predictive value in Alzheimer's disease.
Telomere attrition accounts for cellular aging and is felt to have a pivotal role in Alzheimer's disease. The investigators plan to screen individuals to select those having retinal amyloid then evaluate an oral telomerase activator to determine if its use can alter the RAI over time compared to placebo.
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer Disease||Dietary Supplement: cycloastragenol Dietary Supplement: placebo (for cycloastragenol)||Not Applicable|
Telomerase Activation - Retinal Amyloid Study
Telomere attrition has been linked to the neurodegenerative disease Alzheimer's disease (AD). AD is definitively diagnosed at autopsy a fact that has prompted exhaustive investigations looking for reliable biomarkers of AD. It is known that the clinical signs of AD are the end result of years of accumulation of an aggregated protein substance, amyloid. The retina is part of the brain and recently, a diagnostic technology has been developed that allows detection of retinal amyloid. Tissue studies show a correlation between retinal and cerebral amyloid, and it has been proposed that early detection of retinal amyloid, long before clinical dementia, may offer an opportunity for intervention to slow or halt progressive amyloid deposition. Special imaging technology has been developed that is capable of detecting retinal amyloid via an adapted retinal camera. Neurovision Imaging (NVI) is the company that has developed these testing technologies: both for retinal amyloid detection and measurement.
A study is proposed that will investigate if there is a measurable treatment effect of the telomerase activator TA-65 on retinal amyloid of the participants. It is anticipated that recruiting will primarily be directed at adult children of individuals with clinical AD.
The study will include 50 participants and will have a term of 12 months; it is anticipated that up to 300 individuals will be screened to acquire the participants. The study will be conducted at a single site: Chippewa Valley Eye Clinic, Eau Claire, Wisconsin and/or its satellites. TA-Sciences will sponsor the study, provide telomere length testing on saliva samples collected at the start and conclusion of study. TA-Sciences will also provide active and placebo product for term of study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||48 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||Evaluation of an Oral Telomerase Activator on Retinal Amyloid|
|Actual Study Start Date :||December 1, 2016|
|Actual Primary Completion Date :||October 31, 2018|
|Actual Study Completion Date :||December 31, 2018|
Placebo Comparator: Placebo
Study subjects receiving placebo: Intervention - two capsules, one morning and one night for one year; placebo for cycloastragenol
Dietary Supplement: placebo (for cycloastragenol)
placebo comparator, placebo for cycloastragenol.
Other Name: Silicone dioxide and cellulose
Active Comparator: cycloastragenol
Study subjects receiving cycloastragenol: Intervention - cycloastragenol; oral capsules 8mg. per day (two capsules) one in the morning and one at night for one year.
Dietary Supplement: cycloastragenol
Oral telomerase activator - cycloastragenol.
Other Name: TA-65
- Retinal Amyloid Index (RAI) [ Time Frame: one year. ]Measurement of amyloid fluorescence while taking cycloastragalone or placebo
- Telomere length (kilobases) [ Time Frame: one year ]Telomere length measured in white blood cells isolated from saliva
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02530255
|United States, Wisconsin|
|Chippewa Valley Eye Clinic|
|Eau Claire, Wisconsin, United States, 54701|
|Principal Investigator:||Coad T. Dow, M.D.||Chippewa Valley Eye Clinic|